1. China has given almost a million people experimental Covid vaccine, says company  The Guardian
  2. Oxford-AstraZeneca Covid vaccine shows robust immune response among older adults  CNBC
  3. Oxford Study Confirms Astra Covid Shot’s Response in Elderly  Bloomberg
  4. Good News on Oxford’s COVID-19 Vaccine  VOA Learning English
  5. Almost a million people inoculated with Chinese Covid-19 vaccine: firm  RFI
  6. View Full coverage on Google News

China Sinopharm's COVID-19 vaccine taken by about a million people - CGTN

AstraZeneca and Oxford have published the full coronavirus vaccine study detailing the strong immune response seen in older adults injected with their experimental drug in The Lancet. The COVID-19 vaccine is safe for the elderly and induces the desired immune response against the new virus.AstraZeneca and Oxford have published the full coronavirus vaccine study detailing the strong immune response seen in older adults injected with their experimental drug in The Lancet. The COVID-19 …

A third coronavirus vaccine might deliver results by Christmas – BGR

Mistrust of the medical establishment, based on experience, is behind hesitancy.Mistrust of the medical establishment, based on experience, is behind hesitancy.

Black people have a long history of poor medical treatment – no wonder many are hesitant to take COVID vaccines

Black people have a long history of poor medical treatment – no wonder many are hesitant to take COVID vaccines

Chinese vaccine makers said that China's full-throttled development of COVID-19 vaccines remains in the lead among a roster of effective vaccines, although some Western media and politicians have questioned China for delays in releasing late-stage trial data after US drug makers Pfizer and Moderna's successes. The fact is, however, at least three out of five types of Chinese vaccines against the coronavirus have entered final stage trials, with the latest one beginning phase-III trials in central China's Hunan Province on Thursday.

Nearly 1 million receive vaccine developed by Sinopharm - Global Times

Nearly a million people have taken an experimental coronavirus vaccine developed by Chinese company Sinopharm, the firm said, although it has not yet provided any clear clinical evidence of efficacy.Nearly a million people have taken an experimental coronavirus vaccine developed by Chinese company Sinopharm, the firm said, although it has not yet provided any clear clinical evidence of efficacy.

Almost A Million People Inoculated With Chinese Sinopharm Covid-19 Vaccine

Bloomberg - Are you a robot?

Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus.Scientists at the University of Oxford say their experimental COVID-19 vaccine shows a strong immune response among older people. The early results raise hopes that the vaccine can protect the people most at risk of getting severely ill from the new coronavirus.

Good News on Oxford’s COVID-19 Vaccine

Hundreds of thousands of people in China have already received this vaccine. Now, preliminary trials are showing promising results, although it's too early to say whether it can prevent disease.Hundreds of thousands of people in China have already received this vaccine. Now, preliminary trials are showing promising results, although it's too early to say whether it can prevent disease.

Early Trials Of Sinovac's Vaccine Show It Triggers An Immune Response : Coronavirus Updates : NPR

New Delhi, November 19 Noting that it is natural to prioritise the COVID-19 vaccine distribution process, Health Minister Harsh Vardhan on Thursday said healthcare workers and people aged above 65 yeVardhan said COVID-19 vaccine will be available in the next few months Noting that it is natural to prioritise the COVID-19 vaccine distribution process, Health Minister Harsh Vardhan on Thursday said healthcare workers and people aged above 65 years would be given coronavirus vaccine on priority.

Health care workers, people above 65 will be given priority for Covid vaccine: Harsh Vardhan : The Tribune India

Oxford scientists expect COVID-19 vaccine data by Christmas | 2020/11/19Oxford scientists expect COVID-19 vaccine data by Christmas

Oxford scientists expect COVID-19 vaccine data by Christmas | Taiwan News | 2020/11/19

Vaccine candidate from Oxford University and AstraZeneca has shown promising results in older adults - Anadolu AgencyVaccine candidate from Oxford University and AstraZeneca has shown promising results in older adults - Anadolu Agency

Oxford vaccine produces promising response in elderly

China National Pharmaceutical Group (Sinopharm) also claimed to have received no reports of any 'serious adverse reactions' from those who had received the vaccine.China National Pharmaceutical Group (Sinopharm) also claimed to have received no reports of any 'serious adverse reactions' from those who had received the vaccine.

Coronavirus research: China's Sinopharm vaccine given to 1m people | Daily Mail Online

The UK’s top counter-terrorism cop has suggested society stop allowing people to question the wisdom of a rapid Covid-19 vaccine rollout, regarding such skepticism to be life-threatening “misinformation.”The UK’s top counter-terrorism cop has suggested society stop allowing people to question the wisdom of a rapid Covid-19 vaccine rollout, regarding such skepticism to be life-threatening “misinformation.”

UK terrorism chief calls for ‘national debate’ on criminalizing doubts about Covid-19 vaccine — RT UK News

Early data shows that vaccines work for older people who are more at risk of severe COVID-19.Early data shows that vaccines work for older people who are more at risk of severe COVID-19.

Coronavirus vaccine results are pouring in, and it's good news for older people

Coronavirus vaccine results are pouring in, and it's good news for older people

Turkey is holding talks for the procurement of a potential vaccine developed by Pfizer and its German partner BioNTech, the country’s health minister has said.Turkey is holding talks for the procurement of a potential vaccine developed by Pfizer and its German partner BioNTech, the country’s health minister has said.

Turkey in talks for Pfizer’s COVID-19 vaccine - Turkey News

403 Forbidden

Turkey in talks with Pfizer for 25 million doses of coronavirus vaccine: Health Minister KocaTurkey is in talks with Pfizer for a million doses of the coronavirus vaccine by year-end and 25 million more in 2021, Health Minister Fahrettin Koca said in a statement late...

Turkey in talks with Pfizer for 25 million doses of coronavirus vaccine: Health Minister Koca | Daily Sabah

AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.

AstraZeneca COVID-19 vaccine shows promise in elderly, trial results by Christmas | Reuters

Two weeks after volunteers were administered a second dose, over 99 percent of them had neutralising antibody responses regardless of age.Two weeks after volunteers were administered a second dose, over 99 percent of them had neutralising antibody responses regardless of age.

Oxford vaccine candidate found safe in elderly, offered immunity against SARS-CoV-2 in all age groups- Technology News, Firstpost

Very encouraging results from the Oxford Vaccine trialNovember turned out to be the month of good Covid-19 vaccine news. After the promising interim results of the Pfizer and Moderna Phase 3 trials, the result

Oxford Vaccine Safe And Effective In Older Adults As Well, Phase 2 Data Shows | IFLScience

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

The findings published in ‘Lancet’ are based on 560 healthy adult volunteers and show that the ChAdOx1 nCoV-19 vaccine is “safe and well tolerated” with a lower reactogenicity profile in older adults than in younger adults, meaning the older age groups could build immunity to...The findings published in ‘Lancet’ are based on 560 healthy adult volunteers and show that the ChAdOx1 nCoV-19 vaccine is “safe and well tolerated” with a lower reactogenicity profile in older adults than in younger adults, meaning the older age groups could build immunity to the disease.

Oxford University Covid-19 vaccine ‘encouraging’ for older age groups - world news - Hindustan Times

Researchers said they expect to release their late-stage trial results by Christmas. This would follow rival drugmakers releasing theirs earlier this month.Researchers said they expect to release their late-stage trial results by Christmas. This would follow rival drugmakers releasing theirs earlier this month.

AstraZeneca COVID-19 Vaccine Data Shows Promise In Elderly | HuffPost

A coronavirus vaccine created by a collaboration between drugmaker AstraZeneca and the University of Oxford is showing results that it is safe and triggers a similar immune response among adults of all ages, according to preliminary results of their phase 2 study.A coronavirus vaccine created by a collaboration between drugmaker AstraZeneca and the University of Oxford is showing results that it is safe and triggers a similar immune response among adults of all ages, according to preliminary results of their phase 2 study.

AstraZeneca vaccine shows strong immune response in elderly, appears safe in study

A phase 2 clinical trial has found AstraZeneca’s COVID-19 vaccine delivers similar immune responses in people aged over and under 70 years. The update, which suggests the vaccine is better tolerated by seniors, provides further evidence that prophylactics may work in the people most vulnerable to the coronavirus.A phase 2 clinical trial has found AstraZeneca’s COVID-19 vaccine delivers similar immune responses in people aged over and under 70 years. The update, which suggests the vaccine is better tolerated by seniors, provides further evidence that prophylactics may work in the people most vulnerable to the coronavirus.

AstraZeneca's COVID-19 vaccine shows midphase promise in seniors | FierceBiotech

Pakistan received approval from its main regulator on health, the National Institute of Health, to begin a Phase 3 study using the CanSino vaccine developed in China by CanSino Biologics.If the...Pakistan received approval from its main regulator on health, the National Institute of Health, to begin a Phase 3 study using the CanSino vaccine developed in China by CanSino Biologics.If the...

Incompetence, conspiracy and citizenship

LONDON, Nov 20 ― A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said yesterday as it released its phase 2 trial results. The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side...LONDON, Nov 20 ― A leading Covid-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said yesterday as it released its phase 2 trial results. The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side...

Oxford Covid-19 vaccine safe for older adults, results show | Life | Malay Mail

Portugal has set up a taskforce to come up with a COVID-19 vaccination strategy and hopes to be prepared to start distributing shots as early as January.Portugal has set up a taskforce to come up with a COVID-19 vaccination strategy and hopes to be prepared to start distributing shots as early as January.

Portugal sets up taskforce to prepare COVID-19 vaccine distribution - The Portugal News

The latest breaking news and updates on the coronavirus pandemic from Greater Manchester, the UK and world The latest breaking news and updates on the coronavirus pandemic from Greater Manchester, the UK and world

Coronavirus LIVE updates as government plans for Christmas and scientists hail further vaccine progress - Manchester Evening News

Older people are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use is effective in this group.Older people are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use is effective in this group.

Oxford vaccine is safe and provokes response in adults over 56, study finds | Euronews

Older adults are at higher risk of infection and death from covid-19, and are a priority for immunization whenever a final vaccine emerges from the ongoing trialsOlder adults are at higher risk of infection and death from covid-19, and are a priority for immunization whenever a final vaccine emerges from the ongoing trials

Oxford jab triggers robust immune response in elderly

The phase two trial results raise hopes the jab can protect age groups most at risk from Covid-19.The phase two trial results raise hopes the jab can protect age groups most at risk from Covid-19.

sign-in

Oxford University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing with AstraZeneca after 53 infections among its volunteers, the study's chief investigator said on Thursday. The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa. The first two sets of interim data from vaccine trials from Pfizer and BioNTech last week and Moderna on Monday were released after more than 90 infections among volunteers.Oxford University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing with AstraZeneca after 53 infections among its volunteers, the study's chief investigator said on Thursday. The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa. The first two sets of interim data from vaccine trials from Pfizer and BioNTech last week and Moderna on Monday were released after more than 90 infections among volunteers.

Oxford COVID-19 trial will look at interim Phase III data after 53 infections - investigator

Research has shown that any immunity gained after COVID recovery will most likely last for months, not years.Research has shown that any immunity gained after COVID recovery will most likely last for months, not years.

Why some health officials say herd immunity won’t work with COVID

AstraZeneca and Oxford University jointly developed COVID-19 vaccine-induced immune response in older adults in their phase 2 trial, the British drug AstraZeneca and Oxford University jointly developed COVID-19 vaccine-induced immune response in older adults in their phase 2 trial, the British drug

AstraZeneca and Oxford University: Confirm immune response in elderly, phase 3 vaccine trial in weeks

BEIJING (AFP): Nearly a million people have taken an experimental coronavirus vaccine developed by Chinese company Sinopharm, the firm said, although it has not yet provided any clear clinical evidence of efficacy.BEIJING (AFP): Nearly a million people have taken an experimental coronavirus vaccine developed by Chinese company Sinopharm, the firm said, although it has not yet provided any clear clinical evidence of efficacy.

Almost a million people inoculated with Chinese Covid-19 vaccine: Sinopharm | The Star

Further results showing the effectiveness of the University of Oxford’s coronavirus vaccine are expected to be released in the coming weeks Further results showing the effectiveness of the University of Oxford’s coronavirus vaccine are expected to be released in the coming weeks

GMB's Dr Hilary explains long Covid-19 immunity could last - Liverpool Echo

MORE than 100 new cases of Covid have been recorded in Oxfordshire in a day.MORE than 100 new cases of Covid have been recorded in Oxfordshire in a day.

Daily Covid figures update for Oxford and Oxfordshire | Oxford Mail

Official site of The Week Magazine, offering commentary and analysis of the day's breaking news and current events as well as arts, entertainment, people and gossip, and political cartoons. Early-stage trials indicated that British drug maker AstraZeneca's coronavirus vaccine, which it is developing with the University of Oxford, was safe and effective, according to results published Thursday in The Lancet, a top medical journal. The study of 560 healthy adults found that the vaccine produced a similar immune response in all adults, meaning it could protect older people who face a "significant risk" of developing a severe illness if they are infected with the coronavirus. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society," said Dr. Maheshi Ramasamy, a co-author of the study at the University of Oxford, "but further research will be needed before we can be sure." Harold Maass

AstraZeneca's coronavirus vaccine triggers immune response in older people

Airports equipped with sophisticated time and temperature-sensitive distribution systemAirports equipped with sophisticated time and temperature-sensitive distribution system

Indian airlines, airports set to handle distribution of temperature-sensitive COVID-19 vaccines | India – Gulf News